Nazione: Stati Uniti
Lingua: inglese
Fonte: NLM (National Library of Medicine)
PENTOXIFYLLINE (UNII: SD6QCT3TSU) (PENTOXIFYLLINE - UNII:SD6QCT3TSU)
State of Florida DOH Central Pharmacy
PENTOXIFYLLINE
PENTOXIFYLLINE 400 mg
ORAL
PRESCRIPTION DRUG
Pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. Pentoxifylline extended-release tablets should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.
Pentoxifylline Extended-release Tablets, USP are available as film coated, lavender, unscored, capsule-shaped tablets, each containing 400 mg of pentoxifylline. The tablet is debossed with MYLAN on one side and 357 on the other side. They are supplied by State of Florida DOH Central Pharmacy as follows: Store at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.] Protect from light. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. This product was manufactured by: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 This Product was Repackaged By: State of Florida DOH Central Pharmacy 104-2 Hamilton Park Drive Tallahassee, FL 32304 United States
Abbreviated New Drug Application
PENTOXIFYLLINE - PENTOXIFYLLINE TABLET, FILM COATED, EXTENDED RELEASE STATE OF FLORIDA DOH CENTRAL PHARMACY ---------- DESCRIPTION Each extended-release tablet, for oral administration, contains 400 mg of pentoxifylline and the following inactive ingredients: D&C Red #30 Aluminum Lake, FD&C Blue #2 Aluminum Lake, FD&C Yellow #6 Aluminum Lake, hydroxyethyl cellulose, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, povidone, titanium dioxide and triacetin in an extended-release formulation. Pentoxifylline is a tri-substituted xanthine derivative designated chemically as 1-(5-oxohexyl)-3,7-dimethylxanthine that, unlike theophylline, is a hemorrheologic agent, i.e. an agent that affects blood viscosity. Pentoxifylline is soluble in water and ethanol, and sparingly soluble in toluene. The structural formula is: C H N O M.W. 278.31 Pentoxifylline Extended-release Tablets, USP meet _USP Drug Release Test 6_. CLINICAL PHARMACOLOGY MODE OF ACTION Pentoxifylline and its metabolites improve the flow properties of blood by decreasing its viscosity. In patients with chronic peripheral arterial disease, this increases blood flow to the affected microcirculation and enhances tissue oxygenation. The precise mode of action of pentoxifylline and the sequence of events leading to clinical improvement are still to be defined. Pentoxifylline administration has been shown to produce dose related hemorrheologic effects, lowering blood viscosity, and improving erythrocyte flexibility. Leukocyte properties of hemorrheologic importance have been modified in animal and _in vitro_ human studies. Pentoxifylline has been shown to increase leukocyte deformability and to inhibit neutrophil adhesion and activation. Tissue oxygen levels have been shown to be significantly increased by therapeutic doses of pentoxifylline in patients with peripheral arterial disease. PHARMACOKINETICS AND METABOLISM After oral administration in aqueous solution pentoxifylline is almost completely absorbed. It undergoe Leggi il documento completo